Aptar’s Activ-Film™ Technology Selected to Protect New SARS Rapid Antigen Test for COVID-19 Diagnosis

The QuickVue® SARS Antigen test is a point-of-care rapid antigen test developed by Quidel® Corporation, a leading manufacturer of diagnostic healthcare solutions, that delivers test results in 10 minutes. The visually read test requires no supplemental instrumentation and offers expanded access to affordable and accurate COVID-19 testing that will help meet the urgent testing needs of the global economy, including for those in school systems and rural areas.

 

Aptar CSP Technologies’ Activ-Film™ technology is integrated into the diagnostic kit to protect against moisture and other environmental conditions that could otherwise impact test accuracy. Activ-Film™ leverages Aptar’s proprietary 3-Phase Activ-Polymer™ technology, which provides a broad spectrum of custom-engineered protection in a variety of configurations, such as Activ-Vial™ for housing diagnostics dipsticks and Activ-Tab integrated within diagnostic cassettes.  This material science-based active packaging technology is currently used to protect a range of electrochemical, lateral flow and molecular diagnostic test kits on the market today.

display_title
Aptar’s Activ-Film™ Technology Selected to Protect New SARS Rapid Antigen Test for COVID-19 Diagnosis
Categories
Short Description
AptarGroup, Inc., announced that its Activ-Film™ technology was selected to protect a new SARS Rapid Antigen test for COVID-19 that recently received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).
 
If you would like to feature your company news, press releases, or other updates on our website, you can register and submit content directly through our platform or email us at info@packagingconnections.com.